Details for Patent: 6,762,180
✉ Email this page to a colleague
Which drugs does patent 6,762,180 protect, and when does it expire?
Patent 6,762,180 protects OFEV and is included in one NDA.
Protection for OFEV has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has sixty patent family members in forty-two countries.
Summary for Patent: 6,762,180
Title: | Substituted indolines which inhibit receptor tyrosine kinases |
Abstract: | Indolinones of the formula ##STR1## having an inhibitory effect on receptor tyrosine kinases and cyclin/CDK complexes, as well as on the proliferation of endothelial cells and various tumor cells. Exemplary are: (a) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycar bonyl-2-indolinone, (b) 3-Z-[(1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carbamoy l-2-indolinone, and (c) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-metboxyca rbonyl-2-indolinone. |
Inventor(s): | Roth; Gerald Juergen (Biberach, DE), Heckel; Armin (Biberach, DE), Walter; Rainer (Biberach, DE), Van Meel; Jacobus (Moedling, AT), Redemann; Norbert (Biberach, DE), Tontsch-Grunt; Ulrike (Baden, AT), Spevak; Walter (Oberrohrbach, AT), Hilberg; Frank (Vienna, AT) |
Assignee: | Boehringer Ingelheim Pharma KG (Ingelheim, DE) |
Application Number: | 09/678,682 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,762,180 |
Patent Claim Types: see list of patent claims | Compound; Composition; |
Drugs Protected by US Patent 6,762,180
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Boehringer Ingelheim | OFEV | nintedanib esylate | CAPSULE;ORAL | 205832-001 | Oct 15, 2014 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Boehringer Ingelheim | OFEV | nintedanib esylate | CAPSULE;ORAL | 205832-002 | Oct 15, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 6,762,180
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Germany | 199 49 208 | Oct 13, 1999 |
Germany | 100 42 696 | Aug 31, 2000 |
International Family Members for US Patent 6,762,180
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 026036 | ⤷ Try a Trial | |||
Austria | 439342 | ⤷ Try a Trial | |||
Australia | 1023301 | ⤷ Try a Trial | |||
Australia | 781939 | ⤷ Try a Trial | |||
Bulgaria | 106587 | ⤷ Try a Trial | |||
Bulgaria | 65983 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |